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Abstract
Background: Histopathological diagnosis is important for prognostication and choice of treatment in patients with
cancer in the lung. Metastases to the lungs are common and need to be distinguished from primary lung cancer.
Furthermore, cases with synchronous or metachronous primary lung cancers (although infrequent) are often
handled differently than cases with lung cancer with intrapulmonary metastasis or relapse, respectively. In some
cases, morphology and immunohistochemical staining is not sufficient for certain diagnosis.
Methods: The present study included six cases where molecular genetic analysis in form of pyrosequencing or
targeted next-generation sequencing was of value for certain diagnosis of selected tumours in the lung.
Results: Two of the included cases were rare metastases to the lung; colorectal cancer with IHC profile consistent
with primary lung cancer and malignant adenomyoepithelioma of the breast, respectively, where molecular genetic
analysis was of aid for proving the relationship to the primary tumour. The other four cases were multiple lung
adenocarcinomas where molecular genetic analysis was of aid to distinguish between intrapulmonary metastasis
and synchronous tumour.
Conclusions: Comparison of molecular genetic profile may be an important tool for determination of relationship
between tumours in some situations and should always be considered in unclear cases. Further studies on
concordance and discordance of molecular genetic profiles between spatially or temporally different tumours with
common origin may be helpful for improved diagnostics of pulmonary tumours.
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Background
Histopathological diagnosis is important for choice of
treatment in patients with cancer in the lung. Metastases
to the lungs are common and need to be distinguished
from primary lung cancer, and the treatment of primary
lung cancer is dependent on histopathological type [1–3].
Furthermore, cases with synchronous or metachronous
primary lung cancers (although infrequent [4, 5]) are often
handled differently than cases with lung cancer with intra-
pulmonary metastasis or relapse, respectively.
The basis for histopathological diagnosis is morph-
ology, with the addition of immunohistochemical (IHC)
staining when needed. For example, a limited panel of
thyroid transcription factor 1 (TTF-1) in combination
with estrogen receptor and GATA3 or with cytokeratin
(CK) 7 and CK20 normally separates lung cancer from
breast cancer and colorectal cancer, respectively, with
high accuracy [6–10]. However, sometimes the morpho-
logical appearance may be indistinct and the results of
IHC staining may differ from the typical, with for ex-
ample positive GATA3 reported in 8% of lung adenocar-
cinomas [11–16]. Thus, there is a need for additional
diagnostic analyses or markers, at least in some cases.
It may also be difficult to separate synchronous or meta-
chronous primary lung cancers from intrapulmonary
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metastasis or relapse, respectively. According to the TNM
staging classification and guidelines from the American
College of Chest Physicians (ACCP), separate tumours of
different histopathological type are to be considered syn-
chronous/metachronous [17, 18]. In a case with multiple
tumours of the same histopathological type, the TNM
classification underscores the pathologist’s opinion based
on differences in morphology, IHC and molecular genetic
characteristics and, in case of squamous cell carcinoma,
association with carcinoma in situ for consideration of
synchronous/metachronous primary lung cancer [18]. The
ACCP guidelines also acknowledge different molecular
genetic characteristics and association with carcinoma in
situ (though not limited to only squamous cell carcin-
omas), but emphasize a multidisciplinary approach and
that the tumours should be in separate lobes and not ap-
pear within 2 years, as suggested in the early study by
Martini and Melamed [17, 19, 20]. According to both
guidelines, nodal (mediastinal or with common drainage)
or distant metastases should not be present in synchron-
ous primary lung cancers.
Molecular genetic analysis is normally used for
treatment prediction (such as identification of epider-
mal growth factor receptor [EGFR] mutations). As
mentioned, it is also a recognised tool for distinguish-
ing synchronous primary lung cancer from intrapul-
monary metastasis, and its use in that respect has
been reported already from several years ago, [21] al-
though in our experience underused in the clinical
setting. Single gene assays, which may be sufficient
for treatment prediction today, may be of limited use
in the differential diagnostics of synchronous tumour
vs. intrapulmonary metastasis as most lung adenocar-
cinomas are not EGFR mutated. However, next gener-
ation sequencing (NGS), today implemented at many
sites, should be of more value for comparison of gen-
etic profiles, especially targeted NGS which is more
practical in the clinical setting than whole exome se-
quencing (WES), although the latter may be per-
formed on formalin-fixed paraffin-embedded (FFPE)
tissue as well [22].
Significant mutational intra-tumour heterogeneity
and discordance between primary tumour and metasta-
sis as well as temporal differences during treatment
has been reported in for example renal and ovarian
cancer [23–25]. However, in these studies with exten-
sive sequencing some ubiquitous mutations were com-
monly found in all spatially or temporally different
clones. Furthermore, a high or perfect concordance be-
tween primary tumour and metastasis has been seen
in colorectal and lung cancer and between areas with
different growth patterns within lung adenocarcinomas
when looking at common driver mutations such as
EGFR, KRAS, NRAS and BRAF [26–30].
In the present study, we present six cases where mo-
lecular genetic analysis aided in the diagnostics of pul-
monary tumours. With this case series, we aim to
highlight the topic of comparison of molecular genetic
profiles between two or more tumours as a diagnostic
tool in an accessible way that also is easy to relate to in
the clinical setting.
Methods
Patient selection and investigation
The present study included selected tumours of interest
from lung resections where molecular genetic analysis
had been an aid for definite diagnosis. All cases were
surgically treated for one or more lung tumours at the
Skåne University Hospital, Lund, Sweden during the
years 2011–2016.
The routine investigational work-up included com-
puted tomography (CT), positron emission tomography
with CT and bronchoscopy including endobronchial
ultrasound (EBUS) guided fine needle aspirations from
hilar and mediastinal lymph nodes. In some cases, trans-
thoracic core needle biopsy was also performed. After
surgical resection the lung specimen were fixed in 10%
neutral aqueous formalin (corresponding to 4% formal-
dehyde) for typically 48 h before gross sectioning and
further processing before paraffin-embedding. The rou-
tine sampling included embedding of all tumour if
≤2 cm in size and at least 1 section per cm (i.e. at least 3
if 2.1-3.0 cm) often including one super mega cassette if
more than 2 cm in size.
Immunohistochemical staining
Various IHC stains of relevance were performed in
the clinical setting at the Dept. of Pathology, Lund,
Region Skåne, Sweden, as part of the histopatho-
logical diagnostic procedure. Four micrometer thick
sections from FFPE tissue blocks were pre-treated
and stained in a Ventana Bench-Mark Ultra using
Ventana ultraView Universal DAB Detection Kit (Ventana
Medical Systems, Tucson, AZ). Recommended control
tissue was used on each slide. The clones and ven-
dors for the antibodies included in this study were
TTF-1 clone 8G7G3/1, CK7 clone OV-TL 12/30,
CK20 clone SP33, CDX2 clone EPR2764Y, S100 poly-
clonal, estrogen receptor clone SP1, progesterone re-
ceptor clone 1E2, HER2 clone 4B5, ALK clone D5F3,
all Ventana Medical Systems (Tucson, AZ), napsin A
clone IP64, CK5 clone XM26, both Novocastra/Leica
Biosystems (Kista, Sweden), p63 clone 4A4, smooth
muscle specific actin clone 1A4, both Dako (Glostrup,
Denmark), p40 clone BC28, Histolab Products/Biocare
Medical (Gothenburg, Sweden), and GATA3 clone
L50-823, Cell Marque (Rocklin, CA).
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Fluorescence in situ hybridization (FISH)
FISH for ALK gene rearrangements was performed in
the clinical setting at the Dept. of Pathology, Lund,
Region Skåne, Sweden. During the studied time
period, FISH was initially the only method for ALK
analysis in the routine practice, but was later only
used as complement if ALK IHC staining was unclear.
The Vysis Break Apart probe (Abbott Molecular, Abbott
Park, IL) was used according to the manufacturer's
protocol. Split red and green signals or isolated red signal
in ≥15% of at least 50 nuclei was considered positive
(in practice, normally >100 tumour cell nuclei were
evaluated).
Molecular genetic analysis
Molecular genetic analysis, in form of pyrosequencing
and targeted NGS, was performed at the Dept. of
Clinical Sciences Lund/Dept. of Pathology, Lund, Region
Skåne, Sweden. The analyses were previously validated
for routine clinical diagnostics within the department.
For each sample, a representative area with high fre-
quency of viable malignant cells (at least 10%) was iden-
tified by a pathologist on a hematoxylin-eosin (HE)
stained slide from a FFPE tissue block. Six five-
micrometer thick sections were then taken for molecular
analysis followed by a new HE stained section to ensure
the material being representative.
Pyrosequencing
For single gene analysis (routine analysis in Region
Skåne before 2015), DNA was extracted using the
QIAamp DNA FFPE Tissue Kit for paraffin embedded
tissues according to the manufacturer's protocol (Qiagen,
Hilden, Germany), except that the proteinase K digestion
was extended to overnight. Mutational status for hotspot
mutations in EGFR and KRAS were obtained using
pyrosequencing (PyroMark Q24 sequencer, TheraScreen
EGFR Pyro Kit and TheraScreen KRAS Pyro Kit, DxS/
Qiagen, Hilden, Germany) according to the manufactur-
er's protocol.
Targeted NGS
For targeted NGS, DNA was extracted using the Qiagen
AllPrep kit (Qiagen, Hilden, Germany) for FFPE tissue
and automated on the QIAcube instrument (Qiagen) ac-
cording to the manufacturer's protocol, except that the
proteinase K digestion was extended to overnight. The
NGS-based mutation analysis was performed using the
Illumina TruSight Tumor gene panel on a MiSeq instru-
ment according to manufacturer’s instructions (Illumina,
San Diego, CA, US). Analysed regions included a selected
set of complete exons in 26 genes: AKT1 (exon 2), ALK
(exon 23), APC (exon 15), BRAF (exons 11, 15), CDH1
(exons 8, 9, 12), CTNNB1 (exon 2), EGFR (exons 18, 19,
20, 21), ERBB2 (exon 20), FBXW7 (exons 7, 8, 9, 10, 11),
FGFR2 (exon 6), FOXL2 (exon 1), GNAQ (exons 4, 5, 6),
GNAS (exons 6, 8), KIT (exons 9, 11, 13, 17, 18), KRAS
(exons 1, 2, 3, 4), MAP2K1 (exon 2), MET (exons 1,
4, 13, 15, 16, 17, 18, 20), MSH6 (exon 5), NRAS
(exons 1, 2, 3, 4), PDGFRA (exons 11, 13, 17), PIK3CA
(exons 1, 2, 7, 9, 20), PTEN (exons 1, 2, 3, 4, 5, 6, 7, 9),
SMAD4 (exons 8, 11), SRC (exon 10), STK11 (exons 1, 4,
6, 8), and TP53 (exons 2, 3, 4, 5, 6, 7, 8, 9, 10, 11).
Prior to library preparation a quality control assay was
performed as described in the TruSight Tumor in-
structions. Alignment, quality filtering, variant calling,
and variant annotation were performed using the
standard MiSeq Reporter and VariantStudio analysis
pipeline (Illumina). Only nonsynonymous variants with
a quality score equal to 100 that passed the bi-
directional sequencing quality filter in TruSight Tumor
were considered. Non-targetable mutations with a fre-
quency of <3% were not routinely reported.
Due to change of platform in the clinical setting, for
two cases (no. 5 and 6) the NGS-based mutation ana-
lysis was instead performed using the Ion Ampliseq
Cancer Hotspot panel v2 on an Ion Torrent PGM
instrument according to manufacturer’s instructions
(Thermo Fisher Scientific, Waltham, MA, US). Ana-
lysed regions included a selected set of complete exons
in 50 genes: ABL1 (exon 4–7), AKT1 (exon 3, 6), ALK
(exon 23, 25), APC (exon 16), ATM (exon 8, 9, 12, 17,
26, 34, 35, 36, 39, 50, 54–56, 59, 61, 63), BRAF (exon
11, 15), CDH1 (exon 3, 8, 9), CDKNA2 (exon 2),
CSF1R (exon 7, 22), CTNNB1 (exon 3), EGFR (exon 3,
7, 15, 18–21), ERBB2 (exon 19–21), ERBB4 (exon 3, 4,
6–9, 15, 23), EZH2 (exon 16), FBXW7 (exon 5, 8–11),
FGFR1 (exon 5, 8), FGFR2 (exon 7, 9, 12), FGFR3
(exon 7, 9, 14, 16, 18), FLT3 (exon 11, 14, 16, 20),
GNA11 (exon 5), GNAQ (exon 5), GNAS (exon 8, 9),
HNF1A (exon 3, 4), HRAS (exon 2, 3), IDH1 (exon 4),
IDH2 (exon 4), JAK2 (exon 14), JAK3 (exon 4, 13, 16),
KDR (exon 6, 7, 11, 19, 21, 26, 27, 30), KIT (exon 2,
9–11, 13–15, 17, 18), KRAS (exon 2–4), MET (exon 2,
11, 14, 16, 19), MLH1 (exon 12), MPL (exon 10),
NOTCH1 (exon 26, 27, 34), NPM1 (exon 11), NRAS
(exon 2–4), PDGFRA (exon 12, 14, 15, 18), PIK3CA
(exon 2, 5, 7, 8, 10, 14, 19, 21), PTEN (exon 1, 3, 5–
8), PTPN11 (exon 3, 13), RB1 (exon 4, 6, 10, 11, 14,
17, 18, 20, 21, 22), RET (exon 10, 11, 13, 15, 16),
SMAD4 (exon 3–6, 8–12), SMARCB1 (exon 2, 4, 5, 9),
SMO (exon 3, 5, 6, 9, 11), SRC (exon 14), STK11
(exon 1, 4, 5, 6, 8), TP53 (exon 2, 4–7, 10), VHL (exon
1–3). Alignment, quality filtering, variant calling, and
variant annotation were performed using the standard
Ion Reporter and Torrent Suite software (Thermo
Fisher Scientific). Non-targetable mutations with a fre-
quency of <5% were not routinely reported.
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Results
Case 1
Case 1 was a 58 years old woman who was surgically
treated for one tumour in the liver and one in the lung.
Both were suspected to be metastases from a previous
rectal cancer treated 3 years earlier. There was no evi-
dence of lymph node involvement or other metastases.
Both the lung and liver tumour were adenocarcinomas.
The lung tumour was almost round, 1.5 cm in diameter,
with central necrosis, and exhibited mostly solid but also
partly cribriform growth and with a few separate glandu-
lar structures. The cells were cuboid or irregular to a
greater extent than cylindrical. The liver tumour had
similar morphology but somewhat more resembled colo-
rectal cancer. Both the lung and liver tumour was dif-
fusely positive for CK7 (>90% of the cells) and partially
for TTF-1 (15% of the cells in the lung tumour and in
5% in the liver tumour). CK20, CDX2, and napsin A
were completely negative. See Fig. 1.
The biopsy from the previous rectal cancer was
reviewed, and IHC staining showed positive CK7 while
CK20 and TTF-1 were both negative. The surgical speci-
men had the same profile, but there was very limited
amount of tumour due to neoadjuvant radiotherapy.
Clinico-radiologically metastasis of rectal cancer was
suggested, but considering the IHC profile, a separate
lung cancer with liver metastasis was proposed by the
pathologist, especially since TTF-1 (clone 8G7G3/1) was
positive in the lung and liver tumours, although the
CK7/CK20 profile was the same in the rectal cancer.
Molecular analysis using pyrosequencing showed the
same KRAS mutation (c.38G > A) in both the rectal can-
cer (tested on the biopsy) and the lung tumour, support-
ing that the lung and liver tumours were metastases of
the rectal cancer. Analyses of EGFR (pyrosequencing)
and ALK (FISH) were negative in the lung tumour.
There was insufficient material from the primary tumour
to enable a follow-up NGS analysis for comparison with
the metastases, but a later confirmatory targeted NGS
analysis of the liver metastasis showed the same KRAS
mutation and also a TP53 mutation (c.743G > A).
A second lung metastasis was surgically treated a year
after the first. It had the same morphology as the previ-
ous lung tumour and was partly TTF-1 positive as well.
Two years later, the patient presented with CNS symp-
toms, and a metastasis was found in the frontal lobe.
The metastasis was TTF-1 negative, but otherwise the
same IHC profile with positive CK7 and negative CK20
and CDX2.
Case 2
Case 2 was a 70 years old woman with two histologically
identical lung tumours in the right upper and lower
lobes, respectively, both surgically removed with wedge
Fig. 1 Case 1. Metastases of rectal cancer to the lung and liver with atypical immunohistochemical profile. a-f The metastasis to the lung. a HE,
(b) CK7, (c) CK20, (d) CDX2, (e) TTF-1, (f) napsin A. g-i The metastasis to the liver. g HE, (h) CK7, (i) TTF-1. Note that CK20 and CDX2 were also
negative in the metastasis to the liver (not shown). All images x10 objective
Ericson-Lindquist et al. Diagnostic Pathology  (2017) 12:31 Page 4 of 14
resections. Both tumours were round and about 2 cm in
diameter and rather well-circumscribed. A previous bi-
opsy had suggested possible squamous cell carcinoma,
but the morphology and IHC profile with >90% of the
cells positive for p40, S100 and smooth muscle-specific
actin (CK5 was positive in about 40% of the cells) was
consistent with epithelial-myoepithelial carcinoma. See
Fig. 2. Based on the tumours’ macroscopic appearance
and peripheral location in the lung it was concluded the
tumours were metastases. There was no evidence of
epithelial-myoepithelial carcinoma in the salivary glands
or in accessory salivary glands in the bronchi.
The patient had a previous history of a breast tumour
originally suggested to be at first hand consistent with
ductal carcinoma in situ, approximately 2 cm in size,
surgically treated almost 5 years earlier. The tumours
from the lung and breast were reviewed by several pa-
thologists in Sweden and one international expert with-
out consensus regarding the breast tumour. The
morphology of the peripheral cells in the breast tumour
and the cells of the lung tumours was similar although
the growth pattern when comparing with the breast
tumour as a whole was not perfectly identical and there
were different opinions among pathologists whether the
breast tumour was invasive or not. However, additional
IHC staining of the breast tumour showed positive CK5,
p40, p63, S100 and smooth muscle actin in the basal
and peripheral cells, while the luminal cells were partly
positive for CK5 (about 15% of the luminal cells) and es-
trogen receptor (about 20%). See Fig. 2. Progesterone re-
ceptor and HER2 were negative. The lung tumours were
negative for estrogen and progesterone receptor and
HER2.
After targeted NGS analysis revealed the same
PIK3CA mutation in both the breast and lung tumours
there was a total agreement among the pathologists that
the breast tumour was a malignant adenomyoepithe-
lioma with metastases to the lung. In the breast there
was also a PTEN mutation in a low frequency not seen
in the metastases to the lung (checked for frequency less
than 3%). There were no other mutations detected. See
Table 1 for full NGS data. An initial FISH for ALK gene
rearrangements was inconclusive in one of the metasta-
sis in the lung, and further FISH analyses were not per-
formed after the result of the targeted NGS.
Exactly one year later one more metastasis, this time
in the left lung, was surgically removed. It had the same
morphological appearance as the previous metastases to
Fig. 2 Case 2. Malignant adenomyoepithelioma in the breast with metastases to the lung. a-f The breast tumour. a HE, (b) CK5, (c) p40, (d) S100,
(e) HE, peripheral part of the tumour suspicious for invasion, (f) p40, peripheral part of the tumour. g-l One of the metastases to the lung. g HE,
central part of the tumour, (h) HE, peripheral part of the tumour, (i) CK5, (j) p40, (k) S100, (l) CK7. Note the CK7-positive reactive alveolar epithelium
(positive also for TTF-1, not shown) leading to a papillary appearance at the periphery of the tumour. All images x10 objective.
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the lung. The patient was still alive 18 months later with
no evidence of any more metastases but with a suspicion
of local relapse of the metastasis in the right upper lobe
on a CT scan.
Case 3
Case 3 was a 68 years old male with two rather small
and slowly growing peripheral tumours in the lung, one
in the right upper lobe (5 mm in size) and one in the
right lower lobe (1.8 cm in size). There was no evidence
of lymph node or distant metastases or malignant
pleural exudate. Both tumours were surgically removed
with wedge resections and were TTF-1 positive non-
mucinous adenocarcinomas. The growth pattern was
50% papillary, 25% acinary, 20% lepidic and 5% mucin-
ous (mostly lepidic) in the larger lower lobe tumour and
60% acinary and 40% lepidic in the upper lobe tumour.
See Fig. 3. Both tumours exhibited some spreading
through air spaces (STAS) and the tumour in the lower
lobe also had pleural invasion but without any detected
extension to the pleural surface (i.e. PL1). Furthermore,
in the lower lobe there were a couple of additional, sep-
arate very small foci (<1 mm) of minimally invasive
adenocarcinoma with lepidic and acinary growth, also
detected during the surgical procedure.
The findings of the lower lobe was judged to be a
tumour with metastasis within the same lobe (pT3), but
it was discussed whether the tumour of the upper lobe
represented a separate synchronous tumour (pT1a) or a
metastasis (pT4). Targeted NGS analyses showed the
same KRAS and SMAD4 mutations in both the tumour
of the upper lobe and one of the tumours in the lower
lobe. See Table 1 for full NGS data. IHC staining for
ALK was negative in both tumours. A later analysis of
one of the very small tumours of the lower lobe (not of
relevance for the clinical handling of the patient) re-
vealed the same KRAS mutation while the SMAD4 mu-
tation was not seen.
Consequently, although the patient had a very small
separate tumour with partly different growth pattern in
the upper lobe and no lymph node or distant metastases,
the case was considered to be a metastasis to another
lobe (pT4) based on the identical molecular genetic pro-
file. The patient suffered from severe renal insufficiency
which limited the extent of surgical and chemotherapy
treatment. However, the patient was still alive 18 months
after surgery. At the time, a CT scan showed suspicious
growth of a lung nodule and mediastinal lymph node en-
largement, but EBUS-guided cytology was negative.
Case 4
Case 4 was a 64 years old woman with bilateral tumours
in the upper lobes, both removed with wedge resections
shortly after each other. The tumour in the left upper
lobe was 2.5 cm in size and the one in the right upper
lobe 1.9 cm. Both were TTF-1 positive non-mucinous
adenocarcinomas. The growth pattern was 80% acinary,
15% solid and 5% cribriform (counting as acinary ac-
cording to the WHO classification) in the tumour in the
left lung, while the tumour in the right lung was 60%
acinary, 30% cribriform and 10% solid. See Fig. 4. Al-
though the two tumours were rather small and located
in separate lungs and the patient had no evidence of
lymph node or distant metastasis, it was decided by the
multidisciplinary team to treat the patient as having
metastatic disease (pT1b N0 M1a) since the histological
type and growth pattern was identical. Thus, adjuvant
chemotherapy was administered.
Fig. 3 Case 3. Lung adenocarcinoma with intrapulmonary metastasis with partly different growth patterns but identical genetic profiles. a-d The
tumour of the lower lobe with papillary (predominant), acinary, lepidic and mucinous (about 5%) growth patterns. e-f The tumour of the lower
lobe with acinary (predominant) and lepidic growth patterns. All images HE and x10 objective
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After 3 years there was a suspected local recurrence in
the left upper lobe but no lymph node or distant metas-
tases. Molecular genetic analysis was performed on the
previously resected left upper lobe tumour with pyrose-
quencing showing an EGFR deletion in exon 19
(c.2235_2249del15) and negative IHC for ALK. A follow-
up targeted NGS (being introduced at the time) instead
detected a KRAS mutation in the tumour of the right
upper lobe. The different profiles supported synchron-
ous primary tumours (pT1b and pT1a). See Table 1 for
full NGS data.
Since there was no evidence of lymph node or distant
metastases, it was then decided to surgically remove the
rest of the left upper lobe. The tumour was again a TTF-
1-positive adenocarcinoma with mixed cribriform, acin-
ary and solid growth. Targeted NGS detected the same
EGFR deletion in exon 19 and also found a TP53 muta-
tion with a lower frequency. A later targeted NGS ana-
lysis confirmed the EGFR deletion in the original
tumour of the left upper lobe but did not detect any
TP53 or other mutation.
One year later metastases to lymph nodes 4R and 4 L
were confirmed on cytology from EBUS-guided fine nee-
dle aspirations. Again, a targeted NGS analysis con-
firmed the same EGFR deletion in exon 19 and the same
TP53 mutation. After the start of thyrosine kinase
inhibitor (TKI) therapy, a significant regression of the
enlarged mediastinal lymph nodes was seen.
Case 5
Case 5 was a 65 years old male with a centrally growing
lung tumour engaging both the upper and lower right
lobe and with radiologically suspected mediastinal inva-
sion (i.e. T4). EBUS-guided fine needle aspirations de-
tected a lymph node metastasis to position 12 only (N1).
The cytology favored adenocarcinoma, and targeted
NGS showed no treatment predictive mutations but a
BRAF (c.1406G > T) and a TP53 (c.375G > A) mutation.
Neoadjuvant chemoradiotherapy induced a significant
regression of the tumour, and a right sided pneumonec-
tomy was performed where also a second subpleural
tumour was discovered in the lower lobe. No lymph
node metastases could be detected in the pulmonary or
mediastinal lymph nodes.
Both the central and the subpleural tumours were
TTF-1 and napsin A positive non-mucinous adenocar-
cinomas. The central tumour, measuring at the most
5.3 cm, showed dense central fibrosis with focal micro-
calcifications constituting about 80% of the area, while
the viable tumour was acinary apart from about 5% le-
pidic growth pattern. The subpleural tumour measured
at the most 3.0 cm and exhibited micropapillary (60%)
Fig. 4 Case 4. Synchronous lung adenocarcinomas in upper lobes with similar morphology but different genetic profiles. a-c The KRAS mutated
tumour in the right upper lobe. a HE, x4 objective, b HE, (c) TTF-1. d-f The EGFR mutated tumour in the left upper lobe. d HE, x4 objective, (e) HE,
(e) TTF-1 (note the weaker TTF-1 may be due to suboptimal fixation). g-i Recurrence of the tumour in the left upper lobe. g HE, x4 objective,
(h) HE, (i) TTF-1. All images x10 objective unless otherwise stated
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and papillary (40%) growth. STAS and focal microcalcifi-
cations were seen, but no fibrosis or necrosis. See Fig. 5.
Due to the difference in growth pattern between the
tumours, both were analysed with targeted NGS. The
previously noted BRAF mutation was detected in both
tumours, while only the central tumour had a TP53 mu-
tation but not the same as in the previous cytological
sample. See Table 1 for full NGS data. Based on the
BRAF mutation it was concluded that the subpleural
tumour was an intrapulmonary metastasis rather than a
separate synchronous tumour.
One month after surgery the patient presented with an
advanced intrathoracic infection but was successfully
treated with intravenous and intrathoracic antibiotics.
Two months after the surgery there was no sign of add-
itional metastases or local relapse.
Case 6
Case 6 was a 59 years old non-smoking woman who
presented with a tumour in the right lower lobe, con-
firmed as an adenocarcinoma with a bronchial biopsy.
Pyrosequencing did not show any EGFR mutation (any
further analyses were not performed as the patient was
planned for surgery). An additional suspicious area in
the right upper lobe was detected on a CT scan before
surgery, and the patient underwent a lobectomy of the
lower lobe and a wedge resection of the upper right lobe.
The upper lobe lesion was also an adenocarcinoma. Both
tumours were non-mucinous, 4.0 cm (lower lobe) and
1.1 cm in size respectively. They were regarded similar
in appearance and the upper lobe tumour was consid-
ered an intrapulmonary metastasis (pT4). No lymph
node metastases were found and adjuvant chemotherapy
was initiated.
After four months additional mutational analysis on the
existing material was performed in order to investigate
additional lines of treatment as there was radiological
suspicion of more extensive tumour growth in the upper
lobe than initially suspected. Pyrosequencing showed an
EGFR mutation in the previously resected upper lobe
tumour, while FISH for ALK gene rearrangements was
negative (a later IHC staining for ALK was also negative).
It was assumed that the EGFR mutation was also present
in the lower lobe tumour, and that the first pyrosequenc-
ing analysis on the pre-surgical biopsy had failed to detect
it, being a newly introduced method at the time. As the
disease progressed, TKI was given for four months but
with continued progression with spreading also to the left
lower lobe. A core needle biopsy was taken from the latter
to investigate if an EGFR resistance mutation had devel-
oped, but unexpectedly targeted NGS did not detect any
EGFR mutation. See Table 1 for full NGS data.
In light of this, the tumours were again reviewed. The
tumour in the right lower lobe had 75% micropapillary,
15% acinary, 5% papillary and 5% lepidic growth pattern
and had a <5% mucinous component. The tumour in
the right upper lobe had 100% acinary growth (<5%
solid). Both were positive for TTF-1 and napsin A. The
adenocarcinoma in the left lower lobe had predominant
acinary but also micropapillary and lepidic growth on bi-
opsy. See Fig. 6.
Targeted NGS did not detect any mutations in the tu-
mours of the right lower lobe or the left lower lobe,
while the right upper lobe tumour exhibited the previ-
ously known EGFR mutation and a TP53 mutation.
Based on the morphology and genetic profiles, it was
concluded that the right upper and lower lobe tumours
were synchronous adenocarcinomas and the left lower
lobe tumour a contralateral metastasis from the EGFR
negative right lower lobe tumour (explaining the lack of
effect of TKI treatment). The patient was again put back
on chemotherapy. However, after two months, the on-
cologist asked for PD-L1 analysis and noted that ALK
analysis was missing from both the right lower lobe
tumour and its left lower lobe metastasis. IHC staining
for ALK proved to be positive in both tumours – see
Fig. 6 – why treatment with a TKI for ALK was started.
Discussion
In the present study we describe six cases where mo-
lecular genetic analysis was a valuable or necessary aid
for accurate diagnosis. Two cases concerned metastases
Fig. 5 Case 5. Lung adenocarcinoma with intrapulmonary metastasis with different growth patterns but identical BRAF mutation. a The central
tumour with acinary and lepidic (not shown) growth patterns. b-c The subpleural tumour with micropapillary and papillary growth patterns. All
images HE and x10 objective
Ericson-Lindquist et al. Diagnostic Pathology  (2017) 12:31 Page 9 of 14
to the lungs and proving the relationship to the primary
tumour when morphology and IHC staining was insuffi-
cient for definite diagnosis. The other four cases
concerned synchronous primary lung cancers vs. intra-
pulmonary metastasis. As evident, single gene assays
may be useful in some cases, but targeted NGS may be
even more so, as seen especially in case 2 and 5.
Case 1 is an example of an atypical presentation of a
common diagnosis. Colorectal cancer, a frequent cause
of metastases to the lung, is commonly positive for
CK20 and negative for CK7 [31]. Deviant CK7/CK20
pattern may be related to microsatellite instability, BRAF
mutation and perianal Paget’s disease [32–35]. Positive
TTF-1 (especially clone 8G7G3/1) is also very rare in
colorectal cancer and such tumours still tend to be
CK20+/CK7- [13, 15, 36–39]. Correct diagnosis is im-
portant as there is a difference in treatment and progno-
sis if a separate lung cancer with liver metastasis appears
in a patient with previous rectal cancer instead of metas-
tasis to the liver and lung from the rectal cancer. Al-
though KRAS mutations are common in both colorectal
and lung adenocarcinomas, [40] the finding of the same
mutation in both tumours strongly supported that the
pulmonary tumour was a metastasis. Although this case
could have been solved with morphology only, the mo-
lecular genetic analysis was of aid for correct diagnosis.
Malignant adenomyoepithelioma in the breast, case 2,
is a very rare diagnosis [41]. Epithelial-myoepithelial car-
cinomas are most often found in salivary glands, but
may also derive from submucous glands in bronchi as a
primary lung cancer. The diagnosis may be difficult, and
although morphology and IHC staining is normally suffi-
cient for the diagnosis, in the present case there were
different opinions among experienced senior patholo-
gists (who were all familiar with malignant adenomyoe-
pithelioma) concerning the breast tumour before
molecular genetic analysis. Although PIK3CA mutations
(and especially c.3140A > G) are common in breast can-
cer, [40] the genetic profile strongly suggested that the
lung tumours were metastases from the tumour in the
breast. Although the IHC staining also supported the
diagnosis malignant adenomyoepithelioma the molecular
genetic analysis with targeted NGS was essential for
diagnosis in this case.
Cases 3–6 are examples of multiple lung tumours
where molecular genetic analysis was of aid in the differ-
ential diagnostics between synchronous primary lung
cancer and intrapulmonary metastasis. Case 3 and 5 had
different or partly different growth patterns but identical
genetic profiles. In both cases, it did not really make a
difference for treatment that stage pT4 could be estab-
lished instead of the alternative pT3/pT2b plus a
Fig. 6 Case 6. Synchronous lung adenocarcinomas in right upper and lower lobes with different growth patterns and different genetic profiles
with the contralateral metastasis from the latter. (a-c) The EGFR mutated right upper lobe tumour with acinary growth pattern. (d-f) The right
lower lobe tumour with micropapillary (predominant), acinary and papillary growth patterns. (g-i) The metastasis to the left lower lobe.
(a-b, d-e, g-h) HE, (c, f, i) ALK. All images x10 objective
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separate pT1. However, case 3 is also a good example
that a tumour in a separate lobe may be a metastasis
even in absence of lymph node involvement or distant
metastasis. For example Klempner et al. has also previ-
ously shown that predominantly in situ (lepidic) growth
does not rule out metastatic disease [42]. Case 4 is an
example of adenocarcinomas with identical growth pat-
terns located in different lobes but that were synchron-
ous primary tumours. In case 5, the difference in growth
pattern may of course be at least partly due to the neo-
adjuvant therapy. Case 6 had two adenocarcinomas that
actually showed different growth patterns but was ini-
tially reported as having similar appearance, and optimal
treatment could probably have been given should
complete molecular analysis (with analysis of both EGFR
and ALK) have been performed for both tumours right
from the start.
Comprehensive histopathological subtyping, for adeno-
carcinomas preferably in 5% increments, with comparison
of growth patterns and other morphological features, has
been suggested as a tool for distinguishing synchronous/
metachronous primary lung cancer from metastasis/
relapse [1, 43]. However, non-mucinous lung adeno-
carcinomas with acinary, lepidic, papillary and/or
solid growth are the most common, why subtyping
may be of limited aid in many cases [44–46]. Also,
most lung adenocarcinomas have the same IHC pro-
file with positive CK7, TTF-1 and napsin A [1, 10].
Among the present cases, the results of IHC and
growth patterns in 5% increments was not very help-
ful in cases 3–5, but was so in case 6.
A recent study by Schneider and co-workers showed a
concordance between histological (Martini and Melamed
criteria [19]) and molecular classification of synchronous
primary lung cancers vs. intrapulmonary metastasis in
24 of 27 adenocarcinomas (89%) using a panel of seven
genes (analysis with Sanger sequencing and FISH) [47].
In that study, two cases with different morphological
features exhibited the same KRAS mutation (similar to
our case 5) while one case with morphologically similar
tumours had discordant KRAS mutation status suggest-
ing separate synchronous primary tumours (like our
case 4).
It is noteworthy that only selected cases were included
in the present study. During the same period of time
there were other cases at our department where molecu-
lar genetic analysis was not as helpful. For example, in
one patient with previous colonic cancer three small sus-
pected metastases to the lung were resected. One of the
tumours was a metastasis of the colonic cancer, while
two were non-mucinous lung adenocarcinomas with dif-
ferent growth patterns found in the same lobe. Targeted
NGS revealed a TP53 mutation in one of the lung can-
cers and no mutations in the other. Although a good
concordance for TP53 mutations has been reported be-
tween primary tumour and metastasis in some studies, a
significant discordance has been shown in others (also
our cases 4 and 5), making it a less reliable alteration for
molecular genetic comparisons [29, 48–51]. The pres-
ence of TP53 mutations in normal lung tissue of lung
cancer patients supports its role as an early driver in
lung cancer, [52] and it would be of interest to investi-
gate if some TP53 mutations more than others are prone
to arise early in the process and be concordant between
primary tumours and metastases.
In the literature, there are several studies on synchron-
ous primary lung cancer vs. intrapulmonary metastasis
with variable and rather limited number of included pa-
tients and with different molecular methods used. For ex-
ample, in three rather large studies, Girard and co-
workers used comparative genomic hybridization for
analysis of copy number variation, Warth and co-workers
used Sanger sequencing and loss of heterozygosity, while
Yatabe and co-workers used RT-PCR [21, 28, 53]. Ac-
cording to comprehensive reviews a generally high but
variable (61-100%) concordance for driver mutations
(EGFR and KRAS) between primary tumours and metas-
tases has been reported for lung cancer [30, 54]. It has
been discussed that discordance of molecular genetic
profiles between spatially or temporally different tumours
with common origin may partly be due to methodo-
logical issues [30, 54–56]. In recent well-performed stud-
ies using targeted NGS, Vignot and co-workers found no
discordance in driver mutations between primary lung
cancers and their metastases, while Goswami and co-
workers found a few cases of colonic cancer where a
pathogenic KRAS mutation was not found in distant me-
tastases [49, 50]. However, Pelosi and co-workers found
significant intra-tumour heterogeneity including co-
existence of EGFR and KRAS mutations in minority
clones using laser microdissection of multiple areas in
lung adenocarcinomas [57].
One problem for studies on multiple lung tumours is
the lack of diagnostic gold standard. If histopathological
features with/without addition of radiological findings
are used as basis, it may lead to wrong conclusions
about molecular concordance and discordance between
primary tumours and metastases. But then again, there
is insufficient knowledge when or how often the molecu-
lar genetic profile can be used as the sole diagnostic tool
to determine if two tumours are related or not. Liu and
co-workers argued that a case with three lung cancers,
all with the same EGFR mutation, still were likely to be
synchronous tumours based on about 40 discordant
non-driver mutations found with WES [58]. However,
given the number of mutations typically found with
WES in lung cancers, [26] it is difficult to be certain,
and WES is maybe not more helpful than targeted
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sequencing for comparison of molecular genetic profiles
in these situations.
In the IASLC lung cancer staging project for the up-
coming TNM8 it has been proposed to consider mul-
tiple tumours as from a single tumor source if exactly
matching breakpoints are identified using comparative
genomic hybridization [56] (although alternative tech-
niques for breakpoint analysis is also acknowledged
[59]). Different or same biomarker pattern (e.g. driver
mutations) is considered to be relative arguments that
favour separate or single tumour source, respectively.
We agree it is difficult to draw certain conclusions given
the evidence of today, though in our opinion, different
driver mutations (such as EGFR or KRAS mutations
or ALK or ROS1 rearrangements, like in our cases 4
and 6) probably quite strongly support synchronous/
metachronous tumours. According to the IASLC pro-
posals, multiple lesions of adenocarcinoma in situ, minim-
ally invasive adenocarcinoma or lepidic predominant
adenocarcinoma should be regarded as separate synchron-
ous tumours, [60] supported by highly discordant muta-
tional profiles, also for driver mutations [61].
The number of cases with multiple tumours in the
lung or with a lung tumour where the relationship to a
tumour in another organ cannot be established with
morphology and IHC staining (squamous and neuroen-
docrine cancers excepted) is quite limited. However, at
the present, it seems reasonable to perform treatment
predictive molecular analysis on all tumours in cases
with multiple lung nodules (at least if there are no nodal
or distant metastases) and also in cases where the rela-
tionship between two tumours (including tumours out-
side the lung) is unclear. Consequently, pathology
departments handling these cases need competence in
molecular pathology (including awareness of the possibil-
ities and pitfalls of molecular pathology for diagnostics in
patients with multiple tumours) and continue to introduce
techniques that may be helpful in these situations. Al-
though targeted NGS and other elaborate techniques cost
more than single-gene analyses, the price is still low com-
pared to the cost of e.g. treatment with TKI, and there is
possible gain also for treatment prediction. A more im-
portant limitation is turnaround time, which is often more
important than extreme sensitivity in daily health care.
For the future, there is a continuing need for relatively
large studies on heterogeneity within a single tumour
and between primary tumour and obvious metastasis
(such as lymph node or brain metastasis). The diagnostic
and clinical importance of minority clones should be
further examined. Which genetic changes are stable
from primary tumour to metastases and what techniques
are best at discovering them are both of great interest.
For example, the potential of single cell analyses (e.g.
PCR or NGS) should be further explored in solid tumours
[62]. If comparison of molecular genetic profile alone or
together with histopathological features and/or clinic-
radiological input is the best for diagnostics of multiple
lung tumours also needs to be further investigated.
Conclusions
Comparison of molecular genetic profile may be an im-
portant tool for determination of relationship between
tumours, at least in some cases. Such comparisons
should always be considered in unclear cases and inter-
national guidelines should preferably stress its role in
differential diagnostics of intrapulmonary metastasis vs.
synchronous primary lung cancers. Further studies on
concordance and discordance of molecular genetic pro-
files between spatially or temporally different tumours
with common origin and which analyses are best for
diagnostics of such cases may be helpful for improved
handling of patients with pulmonary tumours.
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